
1. Front Mol Neurosci. 2021 Oct 20;14:778134. doi: 10.3389/fnmol.2021.778134.
eCollection 2021.

Editorial: Gene Therapy in the CNS - Progress and Prospects for Novel Therapies.

Ledri M(1), Sørensen AT(2), Kokaia M(3), Woldbye DPD(2), Gøtzsche CR(2).

Author information: 
(1)Laboratory of Molecular Neurophysiology and Epilepsy, Department of Clinical
Sciences, Epilepsy Center, Faculty of Medicine, Lund University, Lund, Sweden.
(2)Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark.
(3)Experimental Epilepsy Group, Department of Clinical Sciences, Epilepsy Center,
Faculty of Medicine, Lund University, Lund, Sweden.

DOI: 10.3389/fnmol.2021.778134 
PMCID: PMC8564008
PMID: 34744628 

Conflict of interest statement: MK and DW are co-founders and consultants of
CombiGene AB (Lund, Sweden), AS is founder of DolorestBio ApS (Copenhagen,
Denmark), and CG is employed by UCB Nordic A/S (Copenhagen, Denmark). The
remaining author declares that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential
conflict of interest.

